This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sutton-Tyrrell, K. Articles by Kuller, L. H. Search for Related Content PubMed PubMed Citation Articles by Sutton-Tyrrell, K. Articles by Kuller, L. H.

(Stroke. 1995;26:1319-1324.)
© 1995 American Heart Association, Inc.

Articles

Morbidity, Mortality, and Antihypertensive Treatment Effects by Extent of Atherosclerosis in Older Adults With Isolated Systolic Hypertension

Kim Sutton-Tyrrell, DrPH; Hope G. Alcorn, DrPH; Holly Herzog, MPH; Sheryl F. Kelsey, PhD Lewis H. Kuller, MD

From the Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh (Pa).

Correspondence to Kim Sutton-Tyrrell, DrPH, Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, 130 DeSoto St, Pittsburgh, PA 15261.

Background and Purpose The Systolic Hypertension in the Elderly Program (SHEP) demonstrated a significant reduction in stroke and coronary event rates among participants randomly assigned to active blood pressure treatment. Selected participants were evaluated for peripheral atherosclerosis and followed up for cardiovascular events beyond the end of the SHEP trial. Antihypertensive treatment effects were evaluated based on the presence or absence of clinical or subclinical atherosclerosis.

Methods As an ancillary study to SHEP, 190 participants at the Pittsburgh center were evaluated for peripheral atherosclerosis, defined as either an internal carotid stenosis (by duplex scan) or lower extremity arterial disease (identified by ankle blood pressure). Participants were subsequently followed up for cardiovascular events.

Results Estimates of 4-year mortality rates were 4.8% for participants with no atherosclerosis, 16.7% for those with subclinical atherosclerosis, and 23% among those with clinical evidence of atherosclerosis (P<.001). Fatal plus nonfatal cardiovascular event rates were 10.9%, 29.8%, and 58.3% for the three groups, respectively (P<.001). Differences remained significant after adjustment for age, sex, treatment assignment, smoking, and high-density lipoprotein cholesterol. Individuals assigned to placebo at the beginning of SHEP had higher cardiovascular event rates than individuals assigned to active treatment (P=.011), with the most striking difference 3 or more years after the end of the SHEP trial. When this analysis was stratified by the presence or absence of detectable atherosclerosis, the absolute treatment effect was largest among those with evidence of disease.

Conclusions Individuals with systolic hypertension and evidence of peripheral atherosclerosis are at high risk for cardiovascular events. Targeting this group for antihypertensive therapy would result in the prevention of a large number of cardiovascular events.

Key Words: atherosclerosis • carotid stenosis • clinical trials • hypertension

This article has been cited by other articles:

				F. A. Treiber, T. Kamarck, N. Schneiderman, D. Sheffield, G. Kapuku, and T. Taylor Cardiovascular Reactivity and Development of Preclinical and Clinical Disease States Psychosom Med, January 1, 2003; 65(1): 46 - 62. [Abstract] [Full Text] [PDF]

				E. O. Talbott, D. S. Guzick, K. Sutton-Tyrrell, K. P. McHugh-Pemu, J. V. Zborowski, K. E. Remsberg, and L. H. Kuller Evidence for Association Between Polycystic Ovary Syndrome and Premature Carotid Atherosclerosis in Middle-Aged Women Arterioscler Thromb Vasc Biol, November 1, 2000; 20(11): 2414 - 2421. [Abstract] [Full Text] [PDF]

				K. A. Burek, K. Sutton-Tyrrell, M. M. Brooks, B. Naydeck, N. Keller, M. A. Sellers, G. Roubin, R.u. Jandova, and C. S. Rihal Prognostic importance of lower extremity arterial disease in patients undergoing coronary revascularization in the bypass angioplasty revascularization investigation (BARI) J. Am. Coll. Cardiol., September 1, 1999; 34(3): 716 - 721. [Abstract] [Full Text] [PDF]

				L. Kuller, L. Fisher, R. McClelland, L. Fried, M. Cushman, S. Jackson, and T. Manolio Differences in Prevalence of and Risk Factors for Subclinical Vascular Disease Among Black and White Participants in the Cardiovascular Health Study Arterioscler Thromb Vasc Biol, February 1, 1998; 18(2): 283 - 293. [Abstract] [Full Text] [PDF]

				T. W. Kamarck, S. A. Everson, G. A. Kaplan, S. B. Manuck, J. R. Jennings, R. Salonen, and J. T. Salonen Exaggerated Blood Pressure Responses During Mental Stress Are Associated With Enhanced Carotid Atherosclerosis in Middle-Aged Finnish Men : Findings From the Kuopio Ischemic Heart Disease Study Circulation, December 2, 1997; 96(11): 3842 - 3848. [Abstract] [Full Text]

				H. C. Lassila, K. S. Tyrrell, K. A. Matthews, S. K. Wolfson, and L. H. Kuller Prevalence and Determinants of Carotid Atherosclerosis in Healthy Postmenopausal Women Stroke, March 1, 1997; 28(3): 513 - 517. [Abstract] [Full Text]